Action 6600 SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues SciClone Pharmaceuticals (Holdings) Limited

Actions

6600

KYG4271B1023

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:16 02/05/2024 		Varia. 5j. Varia. 1 janv.
18,04 HKD +0,56% Graphique intraday de SciClone Pharmaceuticals (Holdings) Limited +0,22% +29,60%
01/04 SciClone Pharmaceuticals enregistre une hausse de 31 % de son bénéfice en 2023 MT
28/03 Sciclone Pharmaceuticals (Holdings) Limited annonce des changements au sein de sa direction CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit
Sciclone Pharmaceuticals Limited Announces Executive Changes
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3%
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
SciClone Signs Licensing Deal with Menarini for Breast Cancer Drug; Shares Rise 3%
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
SciClone Pharmaceuticals Doses First Patient in Phase 3 Study for Urinary Tract Infection Injection
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China
SciClone Commercially Launches Neuroblastoma Treatment in China
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022
Sciclone Pharmaceuticals Limited Elects Ms. Pan Rongrong as an Executive Director of the Company
SciClone Pharmaceuticals Limited's Equity Buyback announced on May 20, 2022, has expired.
Sciclone Pharmaceuticals Limited Announces Retirement of SHI Cen as Non-Executive Director
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 6600
  4. Actualités SciClone Pharmaceuticals (Holdings) Limited
  5. Autres langues